Search

Your search keyword '"Hadoux, Julien"' showing total 390 results

Search Constraints

Start Over You searched for: Author "Hadoux, Julien" Remove constraint Author: "Hadoux, Julien"
390 results on '"Hadoux, Julien"'

Search Results

2. Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)

5. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

6. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

7. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial

8. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

12. Pneumocystis pneumonia in patients with Cushing's syndrome: A French multicenter retrospective study

19. Impact of COVID-19 on healthcare organisation and cancer outcomes

21. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

23. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors

26. Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network.

27. Interference with VIP to distinguish between real and false VIPoma:national study from the French Endocrine Tumors Group

28. Effectiveness of temozolomide treatment in SDHx mutant and wildtype metastatic pheochromocytoma and paraganglioma - results of a European restrospective multicentre study

29. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

32. La prise en charge des cancers médullaires de la thyroïde en 2024

33. Quelles avancées dans la prise en charge du carcinome anaplasique de la thyroïde en 2024 ?

34. Novel prognostic nomogram for predicting recurrence‐free survival in medullary thyroid carcinoma

35. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network

36. Interference With VIP to Distinguish Between Real and False VIPoma: National Study From the French Endocrine Tumors Group.

37. Contributors

39. ATP6AP2 variant impairs CNS development and neuronal survival to cause fulminant neurodegeneration

41. Transcriptional landscape of a RETC634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers

43. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

44. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

45. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports

46. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

47. Factors associated with survival in anaplastic thyroid carcinoma: A multi-center study from the ENDOCAN-TUTHYREF network

Catalog

Books, media, physical & digital resources